Robeco Institutional Asset Management B.V. Buys 84,125 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Robeco Institutional Asset Management B.V. grew its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 48.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 258,609 shares of the biotechnology company's stock after acquiring an additional 84,125 shares during the period. Robeco Institutional Asset Management B.V. owned 0.11% of ADMA Biologics worth $5,131,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in ADMA Biologics during the fourth quarter worth $19,076,000. JPMorgan Chase & Co. raised its holdings in shares of ADMA Biologics by 272.5% in the 4th quarter. JPMorgan Chase & Co. now owns 767,265 shares of the biotechnology company's stock valued at $13,159,000 after purchasing an additional 561,310 shares during the period. Victory Capital Management Inc. lifted its stake in ADMA Biologics by 52.8% in the 4th quarter. Victory Capital Management Inc. now owns 109,948 shares of the biotechnology company's stock valued at $1,886,000 after purchasing an additional 38,002 shares during the last quarter. Sei Investments Co. lifted its stake in ADMA Biologics by 147.2% in the 4th quarter. Sei Investments Co. now owns 527,272 shares of the biotechnology company's stock valued at $9,043,000 after purchasing an additional 314,013 shares during the last quarter. Finally, Swiss National Bank grew its holdings in ADMA Biologics by 6.6% during the fourth quarter. Swiss National Bank now owns 458,400 shares of the biotechnology company's stock worth $7,862,000 after purchasing an additional 28,500 shares during the period. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Stock Performance

ADMA Biologics stock traded up $0.16 during trading hours on Friday, hitting $18.30. The company had a trading volume of 1,053,349 shares, compared to its average volume of 3,701,918. The firm has a 50-day moving average of $20.24 and a 200 day moving average of $18.72. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.58 and a quick ratio of 3.36. The firm has a market cap of $4.37 billion, a PE ratio of 21.52 and a beta of 0.43. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. ADMA Biologics's revenue for the quarter was up 40.2% on a year-over-year basis. During the same quarter last year, the business posted $0.08 EPS. On average, sell-side analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial raised their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

Insider Activity

In other ADMA Biologics news, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. This represents a 69.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. This represents a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 464,621 shares of company stock valued at $9,644,269. 3.50% of the stock is owned by company insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.